The DirectHit™ Test Panel for Gastrointestinal Cancer is currently being evaluated in ongoing retrospective clinical trials. These trials are being performed in conjunction with several hospitals in Maryland. The trial encompasses esophageal, rectal, colon, pancreatic gastric and duodenal cancers. Drugs/Drug Response Indicators being evaluated include : 5FU/Thymidylate Synthase, Platinum Drugs/ERCC1, and Irinotecan/TOPO I. Early results are encouraging and indicate greater than 80% accuracy for DirectHit™ predictions. These results were published as an abstract at the ASCO Meeting, June 2009 in Orlando, FL. Efforts are underway to organize a number of hospitals both nationally and internationally to conduct a large scale retrospective study of DirectHit™ on G.I. cancers. This study will provide the basic data to support the marketing of DirectHit™ Drug Response Indicator Test Panel for G.I. cancer patients.